Trial Search Results

Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford

This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):


  • Behavioral: Neuropsychological testing




Inclusion Criteria:

   - >/= 18 years-old

   - Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or

   - Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and
   followed primarily by SHC Blood and Bone Marrow transplant providers

   - >/= 6 months from the date of CAR-T infusion

   - Fluent in English

   - Able to attend and participate in in-person testing (Arm I)

   - Able to participate in remote video testing with adequate workspace, computer and
   internet capabilities for a reliable telehealth video connection (Arm II)

Exclusion Criteria:

   - Concurrent enrollment in a CAR-T therapeutics research study

   - Unable to be present for the scheduled testing

   - Unable to participate in testing due to severe cognitive or physical limitation

   - Actively receiving chemotherapy

   - Progressive cancer

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Brian J Scott, MD
Not Recruiting